| BSE: 532488 | Sector: Health care |
| NSE: DIVISLAB | ISIN Code: INE361B01024 |
| BSE 00:00 | 28 May | 2283.45 |
-8.70 (-0.38%) |
OPEN
2310.00 |
HIGH
2310.00 |
LOW
2258.00 |
| NSE 00:00 | 28 May | 2285.10 |
-5.30 (-0.23%) |
OPEN
2295.50 |
HIGH
2300.00 |
LOW
2255.35 |
| OPEN | 2310.00 |
| PREVIOUS CLOSE | 2292.15 |
| VOLUME | 13750 |
| 52-Week high | 2473.65 |
| 52-Week low | 1466.95 |
| P/E | 47.72 |
| Mkt Cap.(Rs cr) | 60,614 |
| Buy Price | 2283.45 |
| Buy Qty | 250.00 |
| Sell Price | 2299.00 |
| Sell Qty | 4.00 |
11.21 am | 9 Apr 2020 | Business Standard
Cipla may see profit-booking around Rs 360 to Rs 367 levels, as per the weekly chart.
11.30 am | 20 Mar 2020 | Business Standard
Whenever the Nifty pharma index has dipped below oversold territory on the Relative Strength Index (RSI), it has seen a stable rise.
12.18 pm | 9 Mar 2020 | Press Trust of India
Divi's Laboratories, established in Hyderabad, is a pharmaceutical company with two manufacturing units
9.34 pm | 25 Feb 2020 | Business Standard
Niche capabilities and absence of regulatory overhangs are other key positives
12.30 pm | 17 Feb 2020 | Business Standard
Except Sun Pharma and Lupin, others have grown significantly and are showing less reversal signals.
4.07 pm | 12 Feb 2020 | Business Standard
All that happened in markets today
2.29 pm | 6 Feb 2020 | Business Standard
Divis Lab hit a new high of Rs 2,080 after the company said it has commenced commercial operations effective from February 5, 2020 from a part of the ...
10.33 am | 1 Feb 2020 | Business Standard
In the past month, Divi's Lab has outperformed the market by surging 10 per cent, as compared to 1.4 per cent decline in the S&P BSE Sensex
8.20 am | 7 Jan 2020 | Business Standard
Godrej Consumer has picked up momentum with decent improvement in the volume to show a positive bias and imply further strength and potential to rise ...
